We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
In this Issue.
- Abstract
This document is a summary of articles published in the journal Clinical Pharmacology & Therapeutics. The first article discusses the potential use of tozorakimab as a treatment for chronic obstructive pulmonary disease (COPD). The study found that tozorakimab was well tolerated and reduced inflammation associated with COPD. The second article focuses on genetic variations in CYP2B6 and CYP2A6 enzymes in sub-Saharan African populations, which can affect patient response to medications. The third article explores the use of proteomics to predict drug concentrations in the liver. The fourth article examines the efficacy of ziritaxestat as a treatment for idiopathic pulmonary fibrosis (IPF) and found that it did not demonstrate efficacy and was associated with increased mortality. The final article discusses the use of a model to predict the risk of Torsade de Pointes (TdP) associated with the drug quinidine.
- Subjects
IDIOPATHIC pulmonary fibrosis; SUB-Saharan Africans
- Publication
Clinical Pharmacology & Therapeutics, 2024, Vol 115, Issue 3, p383
- ISSN
0009-9236
- Publication type
Article
- DOI
10.1002/cpt.3177